Troy Wilson, Angel Investor

Troy Wilson is President, CEO, and Chairman of Kura Oncology, leading the company’s work in precision cancer medicines since 2014. He also serves as Chair of Avidity Biosciences, Board Member at Cartography Biosciences, and Managing Member of Araxes Pharma, extending his influence across biotech innovation. In 2025, he invested in Montara Therapeutics’ $20M seed round, underscoring his commitment to advancing next‑generation therapeutics. His career blends executive leadership, scientific vision, and venture investment, positioning him as a key figure in precision medicine.